FDA Approves First Oral PCSK9 Cholesterol Drug Lipfendra
The Food and Drug Administration approved a first oral PCSK9-class cholesterol pill on Friday, July 17, 2026, creating a new non-statin option that could help millions lower LDL cholesterol.[1]
Reporting said the experimental pill reduced low-density lipoprotein, or LDL, by nearly 60% in trial results.[2] CBS described it as a once-daily, non-statin pill that works by blocking PCSK9 and said it may deliver better results for some people than popular statins, either as an add-on or an alternative.[3]
On Thursday, July 16, 2026, CBS Evening News aired an interview with Columbia University cardiologist Dr. Corey Bradley explaining how the pill works differently from statins and who could benefit most.[3] CBS's Friday morning segment had Chief Medical Correspondent Dr. Jon LaPook expand on PCSK9-targeted therapy and its role in lowering "bad" LDL cholesterol.[1] Fox News framed the approval as "game-changing" in its coverage.[2]
Show source details & analysis (3 sources)
📌 Key Facts
- CBS reported at 8:01 a.m. Central on Friday, July 17, 2026, that the FDA approved a pill form of a powerful PCSK9-class medication that targets LDL cholesterol (FDA).
- On Thursday, July 16, 2026, the CBS Evening News aired an interview with Columbia University cardiologist Dr. Corey Bradley explaining how the newly approved daily cholesterol pill works differently from statins and for whom it may offer better results (Dr. Corey Bradley).
- CBS described the medication as a once-daily, non-statin pill that operates by a different mechanism than traditional statins while still targeting LDL cholesterol reduction (once-daily, non-statin pill).
- The segment highlighted that the pill "may deliver better results for some people" than popular statins, emphasizing its role as an add-on or alternative for patients who do not respond adequately to or tolerate statins well (may deliver better results for some people).
- CBS framed the therapy as a "new pill" that could help millions of people lower their cholesterol, underscoring its potential scale of impact (new pill).
- Chief medical correspondent Dr. Jon LaPook used the Friday, July 17, 2026 morning segment to further explain PCSK9-targeted therapy and its role in reducing "bad" LDL cholesterol, expanding on the prior evening coverage (Dr. Jon LaPook).
📰 Source Timeline (3)
Follow how coverage of this story developed over time
- A CBS News segment published at 8:01 a.m. Central on Friday, July 17, 2026, reported that the FDA has approved a pill form of a powerful PCSK9-class medication that targets LDL cholesterol.
- CBS framed the drug in this segment as a "new pill" that could help millions of people lower their cholesterol, emphasizing its potential scale of impact.
- Chief medical correspondent Dr. Jon LaPook used the TV segment to further explain the mechanism of PCSK9-targeted therapy and its role in reducing "bad" LDL cholesterol, expanding on prior evening coverage.
- On Thursday, July 16, 2026, CBS Evening News aired an interview with Columbia University cardiologist Dr. Corey Bradley explaining how the newly approved daily cholesterol pill works differently from statins and for whom it may offer better results.
- The CBS segment emphasizes that the pill 'may deliver better results for some people' than popular statins, underscoring its potential role as an add-on or alternative for patients who do not respond adequately or tolerate statins well.
- The piece frames the drug in lay terms as a once-daily, non-statin pill, reinforcing that it operates via a different mechanism than traditional statins while still targeting LDL cholesterol reduction.